These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 15230033)

  • 1. [The new class of drugs-- metalloprotease inhibitors -- in the treatment of heart failure].
    Berezin AE
    Klin Med (Mosk); 2004; 82(5):7-15. PubMed ID: 15230033
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical potential of endopeptidase-24.11 inhibitors in cardiovascular disease.
    Wilkins MR
    Biochem Soc Trans; 1993 Aug; 21 ( Pt 3)(3):673-8. PubMed ID: 8224488
    [No Abstract]   [Full Text] [Related]  

  • 3. [Omapatrilat for treatment of heart failure].
    Yamazaki T
    Nihon Rinsho; 2007 May; 65 Suppl 5():173-5. PubMed ID: 17571381
    [No Abstract]   [Full Text] [Related]  

  • 4. [Vasopeptidase inhibitors. Omapatrilat in hypertension and heart failure].
    Heinzl S
    Med Monatsschr Pharm; 2000 Feb; 23(2):38-41. PubMed ID: 10701306
    [No Abstract]   [Full Text] [Related]  

  • 5. Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure.
    Northridge DB; Currie PF; Newby DE; McMurray JJ; Ford M; Boon NA; Dargie HJ
    Eur J Heart Fail; 1999 Mar; 1(1):67-72. PubMed ID: 10937982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omapatrilat.
    Drugs R D; 1999 Apr; 1(4):350-1. PubMed ID: 10566062
    [No Abstract]   [Full Text] [Related]  

  • 7. Combined neutral endopeptidase inhibitors.
    Cuculi F; Erne P
    Expert Opin Investig Drugs; 2011 Apr; 20(4):457-63. PubMed ID: 21323474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure.
    Xu J; Carretero OA; Liu YH; Yang F; Shesely EG; Oja-Tebbe N; Yang XP
    J Card Fail; 2004 Feb; 10(1):83-9. PubMed ID: 14966779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasopeptidase inhibitors--concepts and evidence.
    Ruschitzka F; Corti R; Quaschning T; Hermann M; Lüscher TF
    Nephrol Dial Transplant; 2001 Aug; 16(8):1532-5. PubMed ID: 11477147
    [No Abstract]   [Full Text] [Related]  

  • 10. Vasopeptidase inhibitors in heart failure.
    Dawson A; Struthers AD
    J Renin Angiotensin Aldosterone Syst; 2002 Sep; 3(3):156-9. PubMed ID: 12563565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasopeptidase inhibitors for heart failure: where do we go from here?
    Richards AM
    Eur J Heart Fail; 2003 Aug; 5(4):411-3. PubMed ID: 12921800
    [No Abstract]   [Full Text] [Related]  

  • 12. Vasopeptidase inhibitors: potential role in the treatment of heart failure.
    Trindade PT; Rouleau JL
    Heart Fail Monit; 2001; 2(1):2-7. PubMed ID: 12634892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical significance and therapeutic application of atrial natriuretic peptides].
    Hirata Y
    Nihon Naika Gakkai Zasshi; 1991 Jan; 80(1):112-8. PubMed ID: 1850778
    [No Abstract]   [Full Text] [Related]  

  • 14. Omapatrilat for the management of heart failure and hypertension.
    Husereau DR
    Issues Emerg Health Technol; 2001 Jun; (17):1-4. PubMed ID: 11776285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Omapatrilat--new drug for patients with hypertension and heart failure].
    Dzielska-Olczak M
    Pol Merkur Lekarski; 2005 Oct; 19(112):556-8. PubMed ID: 16379325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omapatrilat.
    Armstrong PW; Lorell BH; Nissen S; Borer J
    Circulation; 2002 Aug; 106(6):e9011-2. PubMed ID: 12187916
    [No Abstract]   [Full Text] [Related]  

  • 17. Ecadotril. (S)-acetorphan, sinorphan.
    Drugs R D; 1999 Apr; 1(4):343-5. PubMed ID: 10566059
    [No Abstract]   [Full Text] [Related]  

  • 18. [Vasopeptidase inhibitors: new pharmacologic classes, new therapeutic opportunities].
    Morganti A
    Cardiologia; 1999 Dec; 44 Suppl 1(Pt 2):829-31. PubMed ID: 12497830
    [No Abstract]   [Full Text] [Related]  

  • 19. Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-centre Dose-ranging Study Investigators.
    Cleland JG; Swedberg K
    Lancet; 1998 May; 351(9116):1657-8. PubMed ID: 9620738
    [No Abstract]   [Full Text] [Related]  

  • 20. [Heart failure and vasopeptidase inhibitors].
    Bareiss P; Ohlmann P; Roul G
    Arch Mal Coeur Vaiss; 2002 Feb; 95 Spec 4(5 Spec 4):51-3. PubMed ID: 11933558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.